低分子肝素联合乙酰半胱氨酸治疗特发性间质性肺炎的疗效分析

doi:10.3969/j.issn.1006-6233.2020.06.036

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1382 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective:To investigate the efficacy of low molecular heparin combined with acetylcysteine (AC) in the treatment of idiopathic interstitial pneumonia (IIP). Methods: A total of 62 patients with IIP treated in the First Hospital of Dandong City from January 2016 to February 2019 were selected and were divided into two groups for prospective study, 31 cases each, with the random number table method. The control group was given comprehensive treatment, and the observation group was added with low-molecular-weight heparin combined with AC. On the basis of this, the total effective rate, pulmonary function indicators [maximum voluntary ventilation (MVV), total lung capacity (TLC), and forced vital capacity (FVC) of the two groups were compared. ], carbon monoxide dispersion per unit of alveolar volume as a percentage of predicted value (DLco / VA% pred)], blood gas indicators [arterial blood oxygen partial pressure (PaO₂), arterial blood carbon dioxide partial pressure (PaCO2)], serum transforming growth factor-β1 (TGF-β1), sialylated glycin 6 (KL-6), peroxisome proliferator-activated receptor gamma (PPARγ) levels, adverse reactions,are compared. And Pearson analysis was performed to analyze the correlation between serum TGF-β1, KL-6, PPARγ before treatment and pre-treatment clinical-imaging-physiological (CRP). Results: The CRP score of the observation group after treatment was lower than that of the control group, and the total effective rate (83.87%) was higher than that of the control group (61.29%, P <0.05). The MVV, TLC, FVC, and DLco / VA% pred of the observation group were higher than the control group after treatment (P <0.05); PaO₂ was higher in the observation group after treatment, PaCO₂ was lower than the control group (P <0.05); serum TGF-β1, KL-6 were lower in the observation group after treatment, and PPARγ was higher than the control group. (P <0.05); serum TGF-β1 and KL-6 before treatment were positively correlated with CRP score before treatment, and serum PPARγ before treatment was negatively correlated with CRP score before treatment (P <0.05). Conclusion:Low-molecular-weight heparin combined with AC in the treatment of IIP can significantly effectively inhibit the progression of pulmonary fibrosis, improve clinical symptoms and blood gas indicators, and improve pulmonary function. The mechanism may be related to up-regulation of PPARγ and down-regulation of TGF-β1 and KL-6

Key words： Low-molecular-weight heparin Acetylcysteine Idiopathic interstitial pneumonia Lung function KL-6 PPARγ

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Yan
	SONG Linfeng
	WANG Lu

Cite this article:

CAI Yan,SONG Linfeng,WANG Lu. Analysis of the Efficacy of Low Molecular Weight Heparin Combined with Acetylcysteine in the Treatment of Idiopathic Interstitial Pneumonia[J]. HeBei Med, 2020, 26(6): 1039-1044.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.06.036 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I6/1039

[1] Isobe K,Issiki T,Sakamoto S,et al.Clinical importance of bcl-2-like 11 deletion polymorphism in idiopathic pulmonary fibrosis[J].Thorac Dis,2019,11(7):2981~2989.
[2] Al-Tamari HM,Dabral S,Schmall A,et al.FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis[J].EMBO Mol Med,2018,10(2):276~293.
[3] Feng F,Zhang J,Wang Z,et al.Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: an updated systematic review and meta-analysis[J].Exp Ther Med,2019,18(1):802~816.
[4] 郑琼娜,武俏俏,马哲乐,等.低分子肝素钠对小鼠实验性肝纤维化干预作用的初步研究[J].中国临床药理学与治疗学,2019,24(5):511~516.
[5] 中华医学会呼吸病学分会间质性肺疾病学组.特发性肺纤维化诊断和治疗中国专家共识[J].中华结核和呼吸杂志,2016,39(6):427~432.
[6] 中华医学会病理学分会胸部疾病学组.中国特发性肺纤维化临床-影像-病理诊断规范[J].中华病理学杂志,2018,47(2):81~86.
[7] Paliogiannis P,Fois AG,Collu C,et al.Oxidative stress-linked biomarkers in idiopathic pulmonary fibrosis: a systematic review and meta-analysis[J].Biomark Med,2018,12(10):1175~1184.
[8] Guo J,Li B,Li W,et al.Chinese herbal medicines compared with N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: protocol for a systematic review[J].Medicine (Baltimore),2018,97(44):e13077.
[9] 王春彬,张询研,李朋梅,等.N-乙酰半胱氨酸治疗特发性肺纤维化疗效与安全性的Meta分析[J].中国药学杂志,2018,53(11):931~937.
[10] Oldham JM,Witt LJ,Adegunsoye A,et al.N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia[J].BMC Pulm Med,2018,18(1):30.
[11] 安方玉,颜春鲁,刘永琦,等.泻肺汤对肺纤维化大鼠TGF-β1/Smads信号转导通路的干预研究[J].中华中医药杂志,2018,33(6):2641~2645.
[12] Mahmoud AM,Hozayen WG,Hasan IH,et al.Umbelliferone ameliorates CCl4-induced liver fibrosis in rats by upregulating PPARγ and attenuating oxidative stress, inflammation and TGF-β1/Smad3 signaling[J].Inflammation,2019,42(3):1103~1116.
[13] Bennett D,Salvini M,Fui A,et al.Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP[J].Inflammation,2019,42(2):463~470.

[1]	. [J]. HeBei Med, 2020, 26(6): 881-886.